A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

Inclusion Criteria: * Subject has provided informed consent prior to any study-specific activities/procedures * Ambulatory postmenopausal women. * Age 55 years or older * Screening BMD value equivalent to a T-score less than or equal to -2.5 at the lumbar spine, total hip, or femoral neck. Exclusion Criteria: * Administration of osteoporosis treatments or bone active treatments within specific timeframes * Vitamin D deficiency * Diseases and conditions that affect bone metabolism (e.g., hypo/hyper-parathyroidism; hypo/hyperthyroidism, unless stable and well-controlled) * Contraindications to denosumab therapy (e.g., hypocalcemia)